bioMerieux (BIM) AI Stock Analysis

• Market Cap: €11.45B
• Dividend Yield: 0.82%
• Average Volume (3M): 107.98K
• Price to Earnings (P/E): 30.4
• Beta (1Y): 0.55
• Revenue Growth: 8.28%
• EPS Growth: -8.08%
• Country: FR
• Employees: 14,147
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.35
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 122,242
• 30 Day Avg. Volume: 107,982
• PEG Ratio: 1.34
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 3.06
• P/FCF Ratio: 37.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €109.80
• Price Target Upside: 13.20% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: €105.00 ▲(8.25% Upside)

bioMerieux's strong financial performance is the most significant factor, supported by consistent revenue growth and solid margins. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which weighs down the overall score.

Positive Factors

Revenue Growth

Sustained ~8.3% revenue growth indicates expanding adoption of diagnostics products and services. Given the company's recurring consumables sales and long-term hospital/lab contracts, this growth profile supports predictable top-line expansion and durable revenue visibility over multiple quarters.

Free Cash Flow Generation

A more than threefold increase in free cash flow signals strong cash conversion and operational resilience. Robust FCF enables sustained R&D investment, capital expenditure, debt repayment or strategic M&A, improving long-term competitive position and financial flexibility.

Strong Balance Sheet

Very high equity ratio and minimal leverage provide balance sheet strength, lowering solvency risk and enabling counter-cyclical investments. This capital structure supports funding of innovation, facility expansion, and potential bolt-on acquisitions without stressing liquidity.

Negative Factors

Modest Return on Equity

ROE of ~10% is respectable but modest for a market-leading diagnostics firm, suggesting capital could be deployed more efficiently. Persistently middling ROE may limit long-term shareholder value creation unless management improves asset utilization or targets higher-return investments.

Declining EPS Trend

Negative EPS growth signals erosion in per-share earnings that can reflect margin compression, higher costs, or one-off items. If persistent, this reduces reinvestment capacity, constrains dividend or buyback programs and indicates management must restore earnings momentum for durable value creation.

Low Income Return for Investors

A sub-1% dividend yield provides limited cash income for yield-focused investors and indicates the company prioritizes reinvestment over cash payouts. Structurally, this may narrow the shareholder base to growth-oriented holders and could be a negative for long-term income investors seeking durable distributions.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

How the Company Makes Money

bioMérieux generates revenue primarily through the sale of its diagnostic products, which include reagents, instruments, and software. The company operates under a business model that combines direct sales and distribution partnerships to reach a global market. Key revenue streams include the sale of diagnostic kits and consumables, which are used in laboratories and healthcare facilities, as well as the provision of services such as maintenance and support for its diagnostic systems. Additionally, bioMérieux benefits from long-term contracts with hospitals and laboratories, enhancing its revenue stability. Strategic partnerships with other healthcare companies and research institutions further contribute to its earnings by expanding its product offerings and market reach. Overall, the company's focus on innovation and quality in diagnostic solutions positions it well within the growing healthcare sector.

bioMerieux Financial Statement Overview

Summary

bioMerieux demonstrates strong financial performance with consistent revenue growth, solid profit margins, and effective cash flow management. The balance sheet shows low leverage and robust equity, though there is room for improvement in return on equity.

Income Statement

bioMerieux has demonstrated strong and consistent revenue growth, with a notable increase of approximately 8.3% from 2023 to 2024. The gross profit margin stands at 55.7%, reflecting effective cost management. The net profit margin is 10.9%, which is solid for the industry. EBIT and EBITDA margins are healthy at 14.8% and 22.5%, respectively, indicating robust operational efficiency.

Balance Sheet

The company exhibits a strong equity base with an equity ratio of 72.9%, indicating financial stability. The debt-to-equity ratio is low at 0.12, suggesting prudent leverage management. The return on equity is 10.3%, which is respectable, though there is room for improvement in generating higher returns on equity.

Cash Flow

bioMerieux's free cash flow has seen significant growth, increasing from €107.1 million in 2023 to €321.5 million in 2024. The operating cash flow to net income ratio is robust at 1.54, showing strong cash conversion from earnings. The free cash flow to net income ratio is 0.74, indicating effective cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.12B	3.98B	3.67B	3.59B	3.38B	3.12B
Gross Profit	2.28B	2.22B	2.06B	1.96B	1.97B	1.74B
EBITDA	958.40M	897.50M	701.30M	811.90M	977.80M	747.70M
Net Income	377.90M	432.20M	357.60M	452.40M	601.10M	404.40M
Balance Sheet
Total Assets	5.37B	5.77B	5.26B	5.19B	4.61B	3.93B
Cash, Cash Equivalents and Short-Term Investments	380.50M	449.80M	352.40M	552.60M	803.50M	389.20M
Total Debt	506.40M	490.70M	518.80M	505.40M	462.50M	481.30M
Total Liabilities	1.43B	1.56B	1.51B	1.54B	1.44B	1.45B
Stockholders Equity	3.93B	4.20B	3.75B	3.60B	3.11B	2.43B
Cash Flow
Free Cash Flow	439.40M	321.50M	107.10M	188.40M	534.60M	305.30M
Operating Cash Flow	787.70M	667.30M	445.40M	475.10M	824.70M	582.80M
Investing Cash Flow	-471.00M	-359.80M	-488.80M	-528.10M	-307.30M	-266.00M
Financing Cash Flow	-173.80M	-212.60M	-122.30M	-244.20M	-140.60M	-175.40M

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 97.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Negative. The current price of 97 is below the 20-day moving average (MA) of 103.74, below the 50-day MA of 106.59, and below the 200-day MA of 114.39, indicating a bearish trend. The MACD of -3.10 indicates Positive momentum. The RSI at 23.45 is Positive, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	75 Outperform	€99.13B	12.66	8.39%	4.77%	-9.82%	119.10%
BIM	66 Neutral	€11.45B	30.39	9.69%	0.82%	8.28%	-8.08%
ERF	64 Neutral	€12.36B	25.72	11.27%	0.97%	6.25%	18.93%
DIM	61 Neutral	€17.62B	70.33	6.65%	0.31%	7.72%	53.84%
ALERS	55 Neutral	€236.63M	100.81	1.32%	―	12.47%	-65.87%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%